Literature DB >> 25514507

The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis.

James D Williamson1, Laura R Sadofsky, Simon P Hart.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating disease of unknown etiology, for which there is no curative pharmacological therapy. Bleomycin, an anti-neoplastic agent that causes lung fibrosis in human patients has been used extensively in rodent models to mimic IPF. In this review, we compare the pathogenesis and histological features of human IPF and bleomycin-induced pulmonary fibrosis (BPF) induced in rodents by intratracheal delivery. We discuss the current understanding of IPF and BPF disease development, from the contribution of alveolar epithelial cells and inflammation to the role of fibroblasts and cytokines, and draw conclusions about what we have learned from the intratracheal bleomycin model of lung fibrosis.

Entities:  

Keywords:  bleomycin; idiopathic pulmonary fibrosis; intratracheal; rodent modeling

Mesh:

Substances:

Year:  2014        PMID: 25514507     DOI: 10.3109/01902148.2014.979516

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  47 in total

Review 1.  Lung Pericytes and Resident Fibroblasts: Busy Multitaskers.

Authors:  Luke Barron; Sina A Gharib; Jeremy S Duffield
Journal:  Am J Pathol       Date:  2016-08-21       Impact factor: 4.307

Review 2.  Using electron microscopes to look into the lung.

Authors:  Matthias Ochs; Lars Knudsen; Jan Hegermann; Christoph Wrede; Roman Grothausmann; Christian Mühlfeld
Journal:  Histochem Cell Biol       Date:  2016-09-29       Impact factor: 4.304

3.  Aucubin Alleviates Bleomycin-Induced Pulmonary Fibrosis in a Mouse Model.

Authors:  Yong Zhou; Ping Li; Jia-Xi Duan; Tian Liu; Xin-Xin Guan; Wen-Xiu Mei; Yong-Ping Liu; Guo-Ying Sun; Li Wan; Wen-Jing Zhong; Dong-Sheng Ouyang; Cha-Xiang Guan
Journal:  Inflammation       Date:  2017-12       Impact factor: 4.092

4.  IL-17A suppresses and curcumin up-regulates Akt expression upon bleomycin exposure.

Authors:  Mahesh Manjunath Gouda; Ashwini Prabhu; Yashodhar Prabhakar Bhandary
Journal:  Mol Biol Rep       Date:  2018-05-28       Impact factor: 2.316

5.  Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation.

Authors:  Yangyang Gu; Bo Huang; Yanfei Yang; Mengdie Qi; Guohua Lu; Dajing Xia; Hequan Li
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

6.  Superoxide Dismutase 3 R213G Single-Nucleotide Polymorphism Blocks Murine Bleomycin-Induced Fibrosis and Promotes Resolution of Inflammation.

Authors:  Gary C Mouradian; Rohit Gaurav; Steve Pugliese; Karim El Kasmi; Brittany Hartman; Laura Hernandez-Lagunas; Kurt R Stenmark; Russell P Bowler; Eva Nozik-Grayck
Journal:  Am J Respir Cell Mol Biol       Date:  2017-03       Impact factor: 6.914

7.  Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion.

Authors:  Rudolf K Braun; Jill M Koch; Timothy A Hacker; David Pegelow; Jaehyup Kim; Amish N Raval; Eric G Schmuck; Denise J Schwahn; Derek J Hei; John M Centanni; Marlowe Eldridge; Peiman Hematti
Journal:  Cytotherapy       Date:  2016-04       Impact factor: 5.414

8.  Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats.

Authors:  Nejat Altintas; Mustafa Erboga; Cevat Aktas; Bulent Bilir; Murat Aydin; Aysun Sengul; Zehra Ates; Birol Topcu; Ahmet Gurel
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

9.  MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.

Authors:  Suzan M Mansour; Hanan S El-Abhar; Ayman A Soubh
Journal:  Inflammopharmacology       Date:  2020-09-10       Impact factor: 4.473

10.  Tannic acid alleviates experimental pulmonary fibrosis in mice by inhibiting inflammatory response and fibrotic process.

Authors:  Nandhine Rajasekar; Ayyanar Sivanantham; Amrita Kar; Santanu Kar Mahapatra; Rajesh Ahirwar; Rajesh K Thimmulappa; Sudhakar Gandhi Paramasivam; Rajasekaran Subbiah
Journal:  Inflammopharmacology       Date:  2020-05-05       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.